Missense driver mutations in cancer are concentrated in a few hotspots 1 . Various mechanisms
have been proposed to explain this skew, including biased mutational processes 2 , …

Cancer immunoediting 1 is a hallmark of cancer 2 that predicts that lymphocytes kill more
immunogenic cancer cells to cause less immunogenic clones to dominate a population. …

To guide the design of immunotherapy strategies for patients with early stage lung tumors,
we developed a multiscale immune profiling strategy to map the immune landscape of early …

Checkpoint blockade immunotherapies enable the host immune system to recognize and
destroy tumour cells 1 . Their clinical activity has been correlated with activated T-cell …

Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines 2 , 3 . Here in a phase I trial of …

It has been posited that anti-tumoral innate activation is driven by derepression of endogenous
repeats. We compared RNA sequencing protocols to assess repeat transcriptomes in …

Background Patients with lung cancers may have disproportionately severe coronavirus
disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific …

Overcoming intrinsic resistance to immune checkpoint blockade for microsatellite stable (MSS)
colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) remains …

Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small
cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying …

T cells are the central drivers of many inflammatory diseases, but the repertoire of tissue-resident
T cells at sites of pathology in human organs remains poorly understood. We examined …